KNSA Stock Forecast & Price Target

Kiniksa Pharmaceuticals is positioned favorably because Arcalyst is delivering strong commercial momentum, with 1Q26 revenue of $214.3MM, up 56% y/y, and FY26 guidance raised to $930MM–$945MM, signaling durable demand. Growth is being driven by expanding prescriber breadth, about 50% repeat prescriber contribution, longer therapy duration approaching ~3 years, and continued earlier-line adoption, while only ~18% of the estimated ~14,000 multiple-recurrence RP population is on therapy, leaving meaningful runway. The company also remains cash flow positive with $468.1MM in cash, and its pipeline—led by KPL-387 with 2H26 dose-focusing data and YE26 Ph 3 initiation, plus KPL-1161 by YE26—supports future franchise expansion and a stronger long-term economic profile.

Kiniksa Pharmaceuticals is facing a negative outlook because its lead commercial asset, Arcalyst, may see slower-than-expected adoption in recurrent pericarditis, limiting the durability of its growth story. Competitive risk is also material, as LLY’s delay of VTX2735 to October 2027 may widen KNSA’s runway in RP, but it also underscores an active field where better-than-expected competitor products could quickly pressure share. The investment case is further weakened by regulatory and commercialization uncertainty, especially if rare-disease biologics fail to command premium pricing at launch, leaving the company exposed despite its U.S.-driven revenue base.